Kala Pharmaceuticals Announces Virtual-Only Format for 2020 Annual Meeting of Stockholders
June 10 2020 - 8:00AM
Business Wire
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical
company focused on the discovery, development and commercialization
of innovative therapies for diseases of the eye, today announced
that its 2020 Annual Meeting of Stockholders (including any
adjournments or postponements, the “Annual Meeting”) has been
changed to a virtual-only format. This decision reflects public
health and safety concerns related to the novel coronavirus
(COVID-19) pandemic and governmental restrictions limiting the
number of people who may gather together, and is intended to
support the health and well-being of Kala’s stockholders, employees
and communities.
As previously announced, the Annual Meeting will be held at 9:00
a.m. Eastern Time, on Thursday, June 25, 2020. Stockholders will
not be able to attend the Annual Meeting in person, but instead
will be able to attend virtually. Stockholders will be able to
participate in the Annual Meeting, vote shares electronically and
submit questions during the live audio webcast of the Annual
Meeting by visiting www.virtualshareholdermeeting.com/KALA2020 and
entering the 16-digit control number found on the proxy card,
voting instruction form or notice previously distributed.
As described in the proxy materials for the Annual Meeting that
were previously distributed, stockholders are entitled to
participate in and vote at the Annual Meeting if they were a
stockholder of Kala as of the close of business on April 27, 2020,
the record date.
Whether or not a stockholder plans to participate in the live
audio webcast of the Annual Meeting, Kala urges all stockholders to
vote and submit their proxies in advance of the Annual Meeting by
one of the methods described in the proxy materials for the Annual
Meeting that were previously provided to the stockholders. The
proxy card included with these proxy materials will not be updated
to reflect the change in location and may continue to be used to
vote stockholder shares in connection with the Annual Meeting.
A notice regarding this change to a virtual meeting format,
additional information regarding the virtual Annual Meeting and
this press release are included in a proxy supplement that Kala has
filed today with the Securities and Exchange Commission.
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the discovery,
development and commercialization of innovative therapies for
diseases of the eye. Kala has applied its AMPPLIFYTM mucus
penetrating particle Drug Delivery Technology to a corticosteroid,
loteprednol etabonate (LE), designed for ocular applications,
resulting in the January 2019 launch of INVELTYS® (loteprednol
etabonate ophthalmic suspension) 1% and its investigational product
candidate, EYSUVISTM (loteprednol etabonate ophthalmic suspension)
0.25%, for which a New Drug Application (NDA) is under review by
the United States Food and Drug Administration (FDA) with a target
action date under the Prescription Drug User Fee Act (PDUFA) set
for October 30, 2020.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200610005023/en/
Investor Contact: Hannah Deresiewicz
hannah.deresiewicz@sternir.com 212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jul 2024 to Aug 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Aug 2023 to Aug 2024